Masahiro Tsuboi

Pulmonary resection for metastatic colorectal cancer: Experiences with 159 patients

Shinji Okumura, Haruhiko Kondo, Masahiro Tsuboi et al. · Journal of Thoracic and Cardiovascular Surgery · 1996 · 240 citations · Full text

Surgical Oncology, Gastrointestinal Oncology, Colorectal Surgery +8

Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer

Jonathan Spicer, Tina Cascone, Murry W Wynes et al. · Journal of Thoracic Oncology · 2024 · 95 citations · Full text

Surgical Oncology, Oncology, Consensus Recommendations +8

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer

Roy S. Herbst, Thomas John, Christian Grohé et al. · Nature Medicine · 2025 · 27 citations · Full text

Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

Christian Grohé, Jonathan W. Goldman, Terufumi Kato et al. · Journal of Clinical Oncology · 2024 · 24 citations

Immunology, Pathology, High-grade Gliomas +19

EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use.

Mary O’Brien, Luis Paz‐Ares, Nitish Jha et al. · Journal of Clinical Oncology · 2022 · 20 citations

Surgical Oncology, Disease Burden, Adjuvant Chemotherapy +17